


Moving Oncology Beyond Trial-and-Error

Personalized In Silico Simulations



The Clinical Challenge

Trial-and-Error approach results in massive patient toxicity and economic waste



The Solution

Transparent (no black-box) simulations of all possible therapeutic options for each patient bypasses Trial-and-Error



The Proof

Our IP-protected tech accurately predicts breast cancer outcomes, identifying patients for chemo de-escalation to reduce toxicity and economic waste*

*Schmiester et al. Clin Cancer Res 2024
Köhn-Luque et al. Cancer Res 2026

Business Model

Go-to-Market Model SaaS CDS

Offer

SaaS platform that ingests RNA results, run simulations and generate CDS reports aligned with clinical guidelines.

Revenue


Annual subscription + site fees. High adoption of solutions like Tempus Next validates institutional demand.

Further business models considered

- Biopharma/RWE services
- Partnership pharma to accelerate drug development
- Out-licensing
- Platform CDx partnerships

Market Opportunity

TOTAL ASK: USD 3.5 million



Activities/Months	0-3	4-6	7-9	10-12	13-15
1. Product Development	\$1.2M		M1		
2. Pilot Production	\$1.0M			M2	
3. Full Launch	\$1.3M				M3

Milestone 1: MVP ready and pilot sites secured

Milestone 2: Multi-site clinical pilots successfully deployed

Milestone 3: Commercial launch with paying customers

Team



Assoc. Prof., Dr.
Alvaro Köhn-Luque
a.k.luque@medisin.uio.no



Prof., Dr. Vessela
Kristensen



Dr. Erlend
Ragnhildstveit

Prof. Arnoldo Frigessi
Prof. Aleix Prat
MSc MBA Anne Ullvestad
MS, BBA Muhammad Hasham
Dr. Leonard Schmiester
Dr. Alan Morgan

SPARK
NORWAY



UNIVERSITETET
I OSLO